<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80446">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696747</url>
  </required_header>
  <id_info>
    <org_study_id>GpCRC-GpR 2-5</org_study_id>
    <nct_id>NCT01696747</nct_id>
  </id_info>
  <brief_title>Gastroparesis Registry 2</brief_title>
  <acronym>GpR2</acronym>
  <official_title>GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To expand a registry of patients for the study of the epidemiology, etiology, and degree of
      morbidity associated with gastroparesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Gastroparesis Registry 2 (GpR 2) will enroll new patients and patients from the initial
      NIDDK Gastroparesis Clinical Research Consortium Gastroparesis Registry (GpR) of
      gastroparesis patients which was initiated in February 2007 and completed in March 2011.

      To continue to follow and expand the data collections of a well-characterized cohort to
      further define the natural history and clinical course of gastroparesis.

      To provide a reliable source for recruitment of well-characterized patients with
      gastroparesis for therapeutic clinical trials, pathophysiological, molecular,
      histopathologic, or other ancillary studies.  These subsequent clinical trials or ancillary
      studies will be conducted under separate study protocols with separate consent processes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Diabetic Gastroparesis</condition>
  <condition>Idiopathic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Diabetic</arm_group_label>
    <description>participants with a primary etiology of diabetic gastroparesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic</arm_group_label>
    <description>participants with a primary etiology of idiopathic gastroparesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Nissen</arm_group_label>
    <description>participants with a primary etiology of post-Nissen fundoplication gastroparesis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma serum DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll patients with gastroparesis and delayed gastric emptying. These
        patients can have either diabetic, idiopathic, or post-Nissen fundoplication
        gastroparesis. In addition, patients with symptoms similar to gastroparesis, but with
        normal gastric emptying will be enrolled as a reference group.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of gastroparesis of at least 12 weeks duration (do not have to be
             contiguous) with varying degrees of nausea, vomiting, early satiety, post-prandial
             fullness, and/or abdominal pain

          -  An etiology of either diabetic, idiopathic, or post-Nissen fundoplication
             gastroparesis

          -  Gastric emptying scintigraphy of solids and liquids test using 4 hours Egg Beaters®
             protocol within the last 6 months with either:

               -  Abnormal gastric emptying rate defined as an abnormal 2 hour (&gt;60% retention)
                  and/or 4 hour (&gt;10% retention) result based on a 4-hour scintigraphic low fat
                  Egg Beaters® gastric emptying study performed at a GpCRC clinical center.

               -  Patients with a normal gastric emptying rate but with symptoms of gastroparesis
                  may be enrolled and classified as possible gastroparesis or gastroparesis-like
                  with normal gastric emptying

          -  Age at least 18 years at initial screening visit

          -  Upper endoscopy results within last 2 years

        Exclusion Criteria:

          -  Inability to comply with or complete the gastric emptying scintigraphy test
             (including allergy to eggs)

          -  Presence of other conditions that could explain the patient's symptoms:

          -  Pyloric or intestinal obstruction as determined by endoscopy, upper GI series or
             abdominal CT scan

          -  Active inflammatory bowel disease

          -  Known eosinophilic gastroenteritis

          -  Primary neurological conditions that could cause nausea and/or vomiting such as
             increased intracranial pressure, space occupying or inflammatory/infectious lesions

          -  Acute liver failure

          -  Advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7 )

          -  Acute renal failure

          -  Chronic renal failure (serum creatinine &gt;3 mg/dL) and/or on hemodialysis or
             peritoneal dialysis

          -  Total or subtotal (near complete) gastric resection, esophagogastrostomy,
             gastrojejunostomy, or gastric bypass. Note: patients with prior fundoplication will
             be eligible for enrollment.

          -  Any other plausible structural or metabolic cause

          -  Any other condition, which in the opinion of the investigator would interfere with
             study requirements

          -  Inability to obtain informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Hamilton, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Tonascia, PhD</last_name>
    <phone>(410) 955-3704</phone>
    <email>jtonasci@jhsph.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aynur Unalp-Arida, MD, PhD</last_name>
    <phone>(410) 614-4851</phone>
    <email>aunalp@jhsph.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Snape, MD</last_name>
      <phone>415-600-1138</phone>
      <email>snapew@sutterhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Candice Lee</last_name>
      <phone>(415) 600-1155</phone>
      <email>LeeCL@cpmcri.org</email>
    </contact_backup>
    <investigator>
      <last_name>William Snape, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5187</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Nguyen, MD</last_name>
      <phone>650-725-3362</phone>
      <email>nguyenlb@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nighat Ullah, MD</last_name>
      <phone>(650) 723-3567</phone>
      <email>nullah@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Linda B Nguyen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Abell, MD</last_name>
      <phone>502-852-7963</phone>
      <email>thomas.abell@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Beatty, RN</last_name>
      <phone>(502) 540-1428</phone>
      <email>karen.beatty@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Abell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pankaj Pasricha, MD</last_name>
      <phone>410-550-6871</phone>
      <email>ppasric1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yale Kim, MSH</last_name>
      <phone>(410) 550-6871</phone>
      <email>yale@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pankaj J Pasricha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William L Hasler, MD</last_name>
      <phone>734-936-8644</phone>
      <email>whasler@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nara Wootten</last_name>
      <phone>(734) 615-6723</phone>
      <email>smao@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William L Hasler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth L Koch, MD</last_name>
      <phone>336-713-7333</phone>
      <email>kkoch@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Judy Hooker</last_name>
      <phone>336-713-7301</phone>
      <email>jhooker@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth L Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry P Parkman, MD</last_name>
      <phone>215-707-7579</phone>
      <email>henry.parkman@temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kellie Simmons, CRNP</last_name>
      <phone>215-707-5477</phone>
      <email>kellie.simmons@temple.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Henry P Parkman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard W McCallum, MD</last_name>
      <phone>915-545-6618</phone>
      <email>richard.mccallum@ttuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalia Vega, RN</last_name>
      <phone>(915) 545-7399</phone>
      <email>Natalia.vega@ttuhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard W McCallum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Sarosiek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://jhuccs1.us/gpcrc/</url>
    <description>Gastroparesis Clinical Research Consortium</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastroparesis</keyword>
  <keyword>idiopathic gastroparesis</keyword>
  <keyword>diabetic gastroparesis</keyword>
  <keyword>post-Nissen gastroparesis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
